Provides that a group policy of accident and health insurance that provides coverage for hospital or medical treatment or services for illness on an expense-incurred basis and is amended, delivered, issued, or renewed after January 1, 2024 (rather than the effective date of the amendatory Act) shall provide coverage, without imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement, for specified methods of cancer testing. Specifies that the provisions do not apply to coverage of prostate cancer screenings to the extent such coverage would disqualify a high-deductible health plan from eligibility for a health savings account under the Internal Revenue Code. Defines “prostate cancer screening” to include medically necessary subsequent follow-up testing as directed by a health care provider (rather than subsequent follow-up testing as directed by a health care provider).